SKLB-677, an FLT3 and Wnt/β-catenin signaling inhibitor, displays potent activity in models of FLT3-driven AML

FLT3 has been identified as a valid target for the treatment of acute myeloid leukemia (AML), and some FLT3 inhibitors have shown very good efficacy in treating AML in clinical trials. Nevertheless, recent studies indicated that relapse and drug resistance are still difficult to avoid, and leukemia...

Descripción completa

Detalles Bibliográficos
Autores principales: Ma, Shuang, Yang, Ling-Ling, Niu, Ting, Cheng, Chuan, Zhong, Lei, Zheng, Ming-Wu, Xiong, Yu, Li, Lin-Li, Xiang, Rong, Chen, Li-Juan, Zhou, Qiao, Wei, Yu-Quan, Yang, Sheng-Yong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group 2015
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620497/
https://www.ncbi.nlm.nih.gov/pubmed/26497577
http://dx.doi.org/10.1038/srep15646

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4620497/
https://www.ncbi.nlm.nih.gov/pubmed/26497577
http://dx.doi.org/10.1038/srep15646

Ejemplares similares